Table 2: Recommended immunization schedule, by COVID-19 vaccine
Based on emerging evidence of the protection provided by the first dose of a two-dose series for COVID-19 vaccines currently authorized in Canada, NACI recommends that in the context of limited COVID-19 vaccine supply and ongoing pandemic disease, jurisdictions should maximize the number of individuals benefiting from the first dose of vaccine by extending the second dose of COVID-19 vaccine up to four months after the first. NACI will continue to monitor the evidence and update this interval as needed.
eports of CVST to VAERS after COVID-19 vaccines
as of April 12, 2021
Janssen COVID-19 vaccine
6 reports of CVST with thrombocytopenia (platelet counts <150K/mm3)
following 6.86 million doses administered
• Reporting rate of 0.87 cases per million doses administered
Pfizer-BioNTech COVID-19 vaccine
0 reports following 97.9 million doses administered
Moderna COVID-19 vaccine
3 reports following 84.7 million doses administered
All 3 with normal platelet counts; onset 2, 6, and 12 days after vaccination